

Press Release

For Immediate Release

Glenmark Generics receives ANDA approval from US-FDA for Ciclopirox Olamine Cream

November 14, 2009: Glenmark Generics Limited (GGL) has received ANDA approval from the United States Food and Drug Administration for Ciclopirox Olamine Cream, 0.77 % and will commence marketing and distribution of this product in the U.S. market.

Ciclopirox Olamine cream generated sales of approximately USD 8 million* in the 12 month period ending September 2009 and is the generic equivalent of Loprox® cream marketed by Medicis. This broad-spectrum antifungal is indicated for the topical treatment of the dermatological infections tinea pedis, tinea cruris, tinea corporis, candidiasis(moniliasis) and tinea(pityriasis) versicolor.

Today's approval augments the breadth of Glenmark's semi-solid line, increasing their overall dermatological portfolio to 13 products. In addition, the Company has a significant number of Abbreviated New Drug Applications pending approval from the FDA and continues to validate their objective towards building a strong presence in this niche segment.

Glenmark is currently authorized to distribute 50 products, translating to over 175 sku's, in the U.S. marketplace and has 46 ANDA's pending approval with the U.S. FDA. Along with a strategic focus dedicated to internal filings, GGI continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio.

*Information provided by IMS Health

About Glenmark Generics Ltd.

Glenmark Generics Limited (GGL) is a subsidiary of Glenmark Pharmaceuticals Limited (Glenmark) and aims to be a global integrated Generic and API leader. GGL has an established presence in North America, EU and Argentina and maintains marketing front-ends in these countries. It primarily sells its FDF products in the United States ("US") and the European Union ("EU"), as well as its oncology FDF products in South America. The Company supplies APIs to customers in approximately 65 countries, including the US, various countries in the EU, South America and India.

About Glenmark Pharmaceuticals Ltd.

Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical company headquartered at Mumbai, India. It is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). Glenmark has eight molecules in various stages of clinical development and is primarily focused in the areas of Inflammation [asthma/COPD, rheumatoid arthritis etc.], Metabolic Disorders [diabetes, obesity, etc.] and Pain [neuropathic pain and inflammatory pain]. The company has a significant presence in branded generics markets across emerging economies including India. GPL along with its subsidiary has twelve manufacturing facilities in four countries and has five R&D centres.

Disclaimer

"Glenmark Generics Limited ("Company") is proposing, subject to market conditions and other considerations, a public issue of its equity shares and has filed a Draft Red Herring Prospectus with SEBI. The Draft Red Herring Prospectus is available on the website of SEBI at www.sebi.gov.in and the respective websites of the BRLMs at www.enam.com and www.kmcc.co.in.

Investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, see the section titled "Risk Factors" of the aforementioned Draft Red Herring Prospectus."

###

For further information, please contact:

Jason D'Souza

Glenmark, Mumbai, India

Tel: [+91 22] 40189919

Email : connect@glenmark-generics.com